<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>PMC</source>
  <date>20140719</date>
  <key>pmc.key</key>
  <document>
    <id>PMC5048367</id>
    <passage>
      <infon key="name_2">surname:Palmqvist;given-names:Sebastian</infon>
      <infon key="name_3">surname:Portelius;given-names:Erik</infon>
      <infon key="name_0">surname:Mattsson;given-names:Niklas</infon>
      <infon key="name_1">surname:Insel;given-names:Philip S</infon>
      <infon key="name_6">surname:Blennow;given-names:Kaj</infon>
      <infon key="alt-title">Niklas Mattsson et&#160;al</infon>
      <infon key="article-id_publisher-id">EMMM201606540</infon>
      <infon key="name_5">surname:Weiner;given-names:Michael</infon>
      <infon key="lpage">1196 1196</infon>
      <infon key="fpage">1184 1184</infon>
      <infon key="year">2016</infon>
      <infon key="name_7">surname:Hansson;given-names:Oskar</infon>
      <infon key="name_4">surname:Zetterberg;given-names:Henrik</infon>
      <infon key="title">Subject Categories</infon>
      <infon key="article-id_doi">10.15252/emmm.201606540</infon>
      <infon key="article-id_pmid">27534871</infon>
      <infon key="source">EMBO Mol Med</infon>
      <infon key="type">front</infon>
      <infon key="kwd">Alzheimer's biomarker CSF neurodegeneration Biomarkers &amp; Diagnostic Imaging Neuroscience</infon>
      <infon key="volume">8 8</infon>
      <infon key="article-id_pmc">5048367</infon>
      <infon key="license">This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</infon>
      <infon key="issue">10</infon>
      <infon key="notes">

 () : &#8211;

 See also: 
CE Teunissen &amp; L Parnetti (October 2016)</infon>
      <offset>0</offset>
      <text>Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease</text>
    </passage>
    <passage>
      <infon key="type">abstract_title_1</infon>
      <offset>85</offset>
      <text>Abstract</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>94</offset>
      <text>Cerebrospinal fluid (CSF) tau (total tau, T&#8208;tau), neurofilament light (NFL), and neurogranin (Ng) are potential biomarkers for neurodegeneration in Alzheimer's disease (AD). It is unknown whether these biomarkers provide similar or complementary information in AD. We examined 93 patients with AD, 187 patients with mild cognitive impairment, and 109 controls. T&#8208;tau, Ng, and NFL were all predictors of AD diagnosis. Combinations improved the diagnostic accuracy (AUC 85.5% for T&#8208;tau, Ng, and NFL) compared to individual biomarkers (T&#8208;tau 80.8%; Ng 71.4%; NFL 77.7%). T&#8208;tau and Ng were highly correlated (&#961;&#160;=&#160;0.79, P&#160;&lt;&#160;0.001) and strongly associated with &#946;&#8208;amyloid (A&#946;) pathology, and with longitudinal deterioration in cognition and brain structure, primarily in people with A&#946; pathology. NFL on the other hand was not associated with A&#946; pathology and was associated with cognitive decline and brain atrophy independent of A&#946;. T&#8208;tau, Ng, and NFL provide partly independent information about neuronal injury and may be combined to improve the diagnostic accuracy for AD. T&#8208;tau and Ng reflect A&#946;&#8208;dependent neurodegeneration, while NFL reflects neurodegeneration independently of A&#946; pathology.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>1316</offset>
      <text>Introduction</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>1329</offset>
      <text>Alzheimer's disease (AD) is a progressive disease characterized by&#160;accumulation of amyloid &#946; (A&#946;) and tau pathologies, neurodegeneration, and cognitive and functional decline. Biomarkers, including cerebrospinal fluid (CSF) measurements, may quantify AD&#8208;related brain changes in&#160;vivo, which has revolutionized research, clinical trial design, and clinical practice (Mattsson et&#160;al, 2015a). CSF total tau (T&#8208;tau) is a well&#8208;studied biomarker, which is increased in neuronal degeneration (Blennow et&#160;al, 2006) and in AD patients already in early clinical stages (Mattsson et&#160;al, 2009; Albert et&#160;al, 2011; McKhann et&#160;al, 2011; Sperling et&#160;al, 2011; Dubois et&#160;al, 2014). CSF neurogranin (Ng) and neurofilament light (NFL) are two other biomarkers that have recently been suggested to measure neurodegeneration in AD. Ng is a post&#8208;synaptic protein (Gerendasy &amp; Sutcliffe, 1997) and a putative marker of synaptic loss in AD (Portelius et&#160;al, 2015), an event which may be closely linked to development of cognitive decline (Portelius et&#160;al, 2015). CSF Ng is increased in AD compared to other dementias (Janelidze et&#160;al, 2016; Wellington et&#160;al, 2016), already in early clinical stages (Kvartsberg et&#160;al, 2015; Tarawneh et&#160;al, 2016). CSF Ng is also associated with brain atrophy (Portelius et&#160;al, 2015; Tarawneh et&#160;al, 2016) and reduced brain glucose uptake (Portelius et&#160;al, 2015). NFL is a putative marker of subcortical large&#8208;caliber axonal degeneration, and increased CSF NFL has been linked to inflammatory diseases (Christensen et&#160;al, 2013) and frontotemporal lobe dementia (Petzold et&#160;al, 2007). But CSF NFL is also relevant in AD (Zetterberg et&#160;al, 2016) since AD not only involves loss of cortical structures but also white matter injury (Migliaccio et&#160;al, 2012) and disconnection of cortical and subcortical regions (Delbeuck et&#160;al, 2003).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>3204</offset>
      <text>It is unknown whether T&#8208;tau, Ng, and NFL provide independent information about AD and whether measuring Ng or NFL in addition to T&#8208;tau improves the diagnostic accuracy for AD. The aim of this study was therefore to compare T&#8208;tau, Ng, and NFL for AD diagnosis and test their associations with other AD hallmarks. Specifically, we tested the hypotheses that (i) combinations of T&#8208;tau, Ng, and NFL increase the diagnostic accuracy for AD versus controls (CN) and for progressive mild cognitive impairment (PMCI) versus stable MCI (SMCI); (ii) T&#8208;tau, Ng, and NFL have different associations with A&#946; pathology and with different clinical stages of AD; and (iii) T&#8208;tau, Ng, and NFL have different associations with other AD features, including cognitive decline, brain atrophy, brain hypometabolism, and white matter hyperintensities (WMH).</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>4052</offset>
      <text>Results</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>4060</offset>
      <text>The study included 93 patients with AD, 187 patients with MCI, and 109 controls (Table&#160;1). For some analyses, we contrasted PMCI (N&#160;=&#160;104) versus SMCI (N&#160;=&#160;65, Table&#160;2).</text>
    </passage>
    <passage>
      <infon key="type">table_caption</infon>
      <offset>4236</offset>
      <text>Demographics</text>
    </passage>
    <passage>
      <infon key="type">table</infon>
      <offset>4249</offset>
      <text>    CN MCI AD  P&#8208;value    N  109 187 93 NA  Age (years) 75.7 (5.2) 74.5 (7.5) 74.7 (8.0) 0.33  Sex (F/M, % F) 54/55 (50%) 62/125 (33%) 41/52 (44%) 0.015   APOE &#949;4 (+/&#8722;, % +) 26/83 (24%) 100/87 (54%) 65/28 (70%) 0.001  Education (years) 15.8 (2.9) 15.8 (3.0) 15.1 (3.2) 0.25</text>
    </passage>
    <passage>
      <infon key="type">table_footnote</infon>
      <offset>4529</offset>
      <text>Continuous data are mean (standard deviation). P&#8208;values tested by Fisher's exact and Kruskal&#8211;Wallis test. CN, healthy controls; MCI, mild cognitive impairment; AD, Alzheimer's disease dementia.</text>
    </passage>
    <passage>
      <infon key="type">table_caption</infon>
      <offset>4727</offset>
      <text>MCI demographics</text>
    </passage>
    <passage>
      <infon key="type">table</infon>
      <offset>4744</offset>
      <text>    SMCI PMCI  P&#8208;value    N  65 104 NA  Age 73. 9 (7.4) 74.5 (7.6) 0.44  Sex (F/M, % F) 21/44 (32%) 37/67 (36%) 0.74   APOE &#949;4 (+/&#8722;, % +) 28/37 (43%) 63/41 (61%) 0.039  Education (years) 16.0 (3.0) 15.9 (3.0) 0.52  Clinical follow&#8208;up (years) 4.5 (2.4) 4.4 (2.5) 0.22</text>
    </passage>
    <passage>
      <infon key="type">table_footnote</infon>
      <offset>5018</offset>
      <text>Continuous data are mean (standard deviation). Note that the total number differs from the complete MCI cohort. For the SMCI versus PMCI comparisons we only included SMCI subjects with at least 2&#160;years of follow&#8208;up. P&#8208;values tested by Fisher's exact test and Mann&#8211;Whitney U&#8208;test. SMCI, stable mild cognitive impairment; PMCI, progressive mild cognitive impairment.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>5392</offset>
      <text>Demographics</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>5405</offset>
      <text>T&#8208;tau and Ng were higher in females than in males (T&#8208;tau: median 90&#160;ng/l versus 80&#160;ng/l, P&#160;=&#160;0.036; Ng: 467&#160;ng/l versus 374&#160;ng/l, P&#160;=&#160;0.0024), while NFL was higher in males (7.22 versus 7.04 [log] ng/l, P&#160;&lt;&#160;0.001). T&#8208;tau and Ng were higher in APOE &#949;4+ than in APOE &#949;4&#8722; participants (T&#8208;tau: 103&#160;ng/l versus 69&#160;ng/l, P&#160;&lt;&#160;0.001; Ng: 491&#160;ng/l versus 343&#160;ng/l, P&#160;&lt;&#160;0.001), while NFL did not differ by APOE &#949;4 status (7.16 versus 7.09 [log] ng/l, P&#160;=&#160;0.15). NFL was higher (&#961;&#160;=&#160;0.32, P&#160;&lt;&#160;0.001) and Ng was lower (&#961;&#160;=&#160;&#8722;0.13, P&#160;=&#160;0.013) in older people, while T&#8208;tau (&#961;&#160;=&#160;&#8722;0.0092, P&#160;=&#160;0.86) did not vary with age. Likewise, NFL was higher (&#961;&#160;=&#160;0.10, P&#160;=&#160;0.040) and Ng was lower (&#961;&#160;=&#160;&#8722;0.13, P&#160;=&#160;0.0089) in people with higher education, while T&#8208;tau had no correlation with education (&#961;&#160;=&#160;&#8722;0.072, P&#160;=&#160;0.16).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>6276</offset>
      <text>Correlations between CSF T&#8208;tau, Ng, and NFL</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>6322</offset>
      <text>T&#8208;tau, Ng, and NFL were all correlated (Fig&#160;1A&#8211;C), and the correlation between T&#8208;tau and Ng was especially strong. T&#8208;tau, Ng, and NFL correlated negatively with A&#946;42 (Fig&#160;1D&#8211;F).</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>6513</offset>
      <text>Biomarker correlations</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>6536</offset>
      <text>Associations between CSF T&#8208;tau, Ng, and NFL (panels A&#8211;C) and between these biomarkers and CSF A&#946;42 (panels D&#8211;F). Black circles: CN (n&#160;=&#160;109), red triangles: MCI (n&#160;=&#160;187), blue crosses: AD (n&#160;=&#160;93). Associations are shown for Spearman correlations. A&#946;42 and T&#8208;tau were measured using the INNOBIA AlzBio3 kit (Fujirebio, Ghent, Belgium), Ng was measured using an in&#8208;house immunoassay for Ng (Portelius et&#160;al, 2015) and NFL was measured using the NF&#8208;light&#174; ELISA kit (Uman Diagnostics, Ume&#229;, Sweden).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>7058</offset>
      <text>  </text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>7061</offset>
      <text>Diagnostic accuracy of CSF T&#8208;tau, Ng, and NFL</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>7109</offset>
      <text>We tested accuracies for AD dementia versus CN and for PMCI versus SMCI using logistic regression models (Table&#160;3). T&#8208;tau, Ng, and NFL were all significant predictors of AD. For single predictors, T&#8208;tau had the highest accuracy, followed by NFL and Ng. The model with the highest accuracy used all biomarkers together (AUC 85.5%). For PMCI versus SMCI, T&#8208;tau and Ng, but not NFL, were significant individual predictors. No combination had higher AUC than the model using only T&#8208;tau. We also evaluated models adjusted for demographics (age, sex, and education) and demographics plus A&#946;42 (Table&#160;EV1). These models had higher AUCs than the basic models without covariates, but the overall results and relationship between the different models were similar.</text>
    </passage>
    <passage>
      <infon key="type">table_caption</infon>
      <offset>7875</offset>
      <text>Diagnostic accuracy of CSF biomarkers</text>
    </passage>
    <passage>
      <infon key="type">table</infon>
      <offset>7913</offset>
      <text>   Groups Model T&#8208;tau Ng NFL AUC (95% CI) AIC   AD versus CN T&#8208;tau only  1.61 (&lt;&#160;0.001)    80.8 (74.3&#8211;86.4) 216.3  Ng only   0.85 (&lt;&#160;0.001)   71.4a (64.1&#8211;77.9) 254.7  NFL only    1.38 (&lt;&#160;0.001)  77.7 (71.4&#8211;83.8) 228.9  T&#8208;tau &amp; Ng  2.11 (&lt;&#160;0.001)  &#8722;0.56 (0.074)  81.4b (75.2&#8211;87.3) 215.0  T&#8208;tau &amp; NFL  1.33 (&lt;&#160;0.001)    0.98 (&lt;&#160;0.001)  84.9a,b,c (79.8&#8211;89.8) 198.1  Ng &amp; NFL   0.61 (0.0016)   1.19 (&lt;&#160;0.001)  80.6b,c,e (74.7&#8211;86.2) 219.7  T&#8208;tau &amp; Ng &amp; NFL  1.80 (&lt;&#160;0.001)  &#8722;0.52 (0.11)  0.99 (&lt;&#160;0.001)  85.5a&#8211;f (80.6&#8211;90.6) 197.4  PMCI versus SMCI T&#8208;tau only  0.56 (0.0035)    67.7 (58.6&#8211;75.2) 219.2  Ng only   0.39 (0.027)   60.4a (50.6&#8211;68.8) 223.9  NFL only   0.32 (0.069) 58.9 (48.8&#8211;68.0) 225.6  T&#8208;tau &amp; Ng  0.60 (0.038)  &#8722;0.046 (0.86)  68.2b (58.4&#8211;76.2) 221.2  T&#8208;tau &amp; NFL  0.52 (0.0082)   0.20 (0.23) 67.5b,c (58.1&#8211;76.0) 219.7  Ng &amp; NFL   0.38 (0.29)  0.30 (0.076) 63.0 (54.2&#8211;72.3) 222.5  T&#8208;tau &amp; Ng &amp; NFL 0.49 (0.10) 0.028 (0.92) 0.21 (0.23) 67.3b,c (59.0&#8211;76.5) 221.7</text>
    </passage>
    <passage>
      <infon key="type">table_footnote</infon>
      <offset>8945</offset>
      <text>A separate logistic regression model was fit for each combination of neurodegeneration biomarkers in AD dementia versus CN and in PMCI versus SMCI. The table includes coefficients (log odds) with P&#8208;values, AUC, and AIC. For AUC, the letters a&#8208;f indicate significant differences (P&#160;&lt;&#160;0.05, tested by bootstrap) versus other models: T&#8208;tau (a), Ng (b), NFL (c), T&#8208;tau &amp; Ng (d), T&#8208;tau &amp; NFL (e), Ng &amp; NFL (f). Bold values indicate significant associations. AD, Alzheimer's disease dementia; AIC, Akaike information criterion; AUC; area under the receiver operating characteristic curve; CN, healthy controls; PMCI, progressive mild cognitive impairment; SMCI, stable mild cognitive impairment.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>9647</offset>
      <text>We noted that there was a special relationship between T&#8208;tau and Ng, so that when Ng was adjusted for T&#8208;tau, the effect of Ng on AD diagnosis often changed from positive to negative (for example, from &#946;&#160;=&#160;0.85 to &#946;&#160;=&#160;&#8722;0.56, Table&#160;1). When adjusting for other covariates, this inversed effect of Ng was statistically significant, indicating that low Ng was associated with AD when the models were adjusted for T&#8208;tau (Table&#160;EV1).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>10091</offset>
      <text>Biomarker combinations for classification of patients and controls</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>10158</offset>
      <text>We extracted classification tables from the logistic regression models generated above, based on a threshold of 50% for the predicted probability of the logistic regression models. The results are summarized in Table&#160;4. T&#8208;tau correctly classified 59 of 93 AD and 90 of 109 CN. Adding Ng improved the classification of CN to 93 of 109, without changing the classification of AD. In contrast, adding NFL improved the classification of AD to 61 of 93 but worsened the classification of CN to 87 of 109. Adding both Ng and NFL improved the classification of both AD (66 of 93, a relative increase of 12% from 59 of 93) and only slighly affected the classification of CN (89 of 109 CN). When also adjusting for age, sex, and A&#946;42, NFL had the highest correct classification rate (correctly classifying 79 of 93 AD and 93 of 109 CN), and there was no improvement when combining biomarkers. For PMCI versus SMCI, all models had high correct classification of PMCI and poor classification of SMCI. Adjusting for age, sex, and A&#946;42 greatly improved classification of SMCI.</text>
    </passage>
    <passage>
      <infon key="type">table_caption</infon>
      <offset>11228</offset>
      <text>Classification tables</text>
    </passage>
    <passage>
      <infon key="type">table</infon>
      <offset>11250</offset>
      <text>   Biomarkers AD versus CN PMCI versus SMCI  Correct overall, % Correct AD Correct CN Correct overall, % Correct PMCI Correct SMCI   No covariates  T&#8208;tau only 73.8 59/93 90/109 68.0 95/104 20/65  Ng only 66.3 46/93 88/109 63.9 98/104 10/65  NFL only 72.3 60/93 86/109 64.5 102/104 7/65  T&#8208;tau &amp; Ng 75.2 59/93 93/109 68.6 96/104 20/65  T&#8208;tau &amp; NFL 73.3 61/93 87/109 69.8 96/104 22/65  Ng &amp; NFL 70.8 59/93 84/109 65.1 95/104 15/65  T&#8208;tau &amp; Ng &amp; NFL 76.7 66/93 89/109 69.8 96/104 22/65  Adjusted for age, sex, education, and A&#946;42  T&#8208;tau only 81.7 73/93 92/109 72.7 90/104 33/65  Ng only 75.7 72/93 81/109 71.6 90/104 31/65  NFL only 85.1 79/93 93/109 73.4 93/104 31/65  T&#8208;tau &amp; Ng 80.7 74/93 89/109 72.8 90/104 33/65  T&#8208;tau &amp; NFL 84.7 78/93 93/109 73.4 93/104 31/65  Ng &amp; NFL 84.7 79/93 92/109 71.0 89/104 31/65  T&#8208;tau &amp; Ng &amp; NFL 84.7 78/93 93/109 72.1 91/104 31/65</text>
    </passage>
    <passage>
      <infon key="type">table_footnote</infon>
      <offset>12130</offset>
      <text>Classification tables from logistic regression models using a threshold of 50% for predicted probabilities. AD, Alzheimer's disease dementia; CN, healthy controls; PMCI, progressive mild cognitive impairment; SMCI, stable mild cognitive impairment.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>12379</offset>
      <text>CSF T&#8208;tau, Ng, and NFL across clinical diagnoses and A&#946; pathology</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>12448</offset>
      <text>For the next set of analyses, participants were grouped based on the combination of clinical diagnosis and A&#946; pathology (CN A&#946;&#8722;, N&#160;=&#160;69; CN A&#946;+, N&#160;=&#160;40; MCI A&#946;&#8722;, N&#160;=&#160;50; MCI A&#946;+, N&#160;=&#160;137; AD A&#946;&#8722;, N&#160;=&#160;8; AD A&#946;+, N&#160;=&#160;85). We performed different comparisons of CSF biomarkers between these groups. All models were adjusted for age and sex.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>12810</offset>
      <text>We first compared CSF biomarkers between A&#946;&#8208;positive and A&#946;&#8208;negative people within diagnosis (Fig&#160;2 and upper part of Table&#160;5). A&#946; positivity was associated with increased T&#8208;tau in all diagnostic groups and with increased Ng in MCI, but never with NFL.</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>13074</offset>
      <text>Biomarkers by diagnosis and amyloid pathology</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>13120</offset>
      <text>CSF T&#8208;tau (panel A), Ng (panel B) and NFL (panel C) in different combinations of clinical diagnosis and A&#946; pathology (CN A&#946;&#8722;, n&#160;=&#160;69; CN A&#946;+, n&#160;=&#160;40; MCI A&#946;&#8722;, n&#160;=&#160;50; MCI A&#946;+, n&#160;=&#160;137; AD A&#946;&#8722;, n&#160;=&#160;8; AD A&#946;+, n&#160;=&#160;85) (see Table&#160;5 for comparisons between groups). Biomarker levels are standardized to z&#8208;scores and shown in box plots (indicating median and interquartile ranges; whiskers are defined as quartiles 1 and 3&#160;&#177;&#160;1.5 &#215; interquartile range, respectively). A&#946;42 and T&#8208;tau were measured using the INNOBIA AlzBio3 kit (Fujirebio, Ghent, Belgium), Ng was measured using an in&#8208;house immunoassay for Ng (Portelius et&#160;al, 2015), and NFL was measured using the NF&#8208;light&#174; ELISA kit (Uman Diagnostics, Ume&#229;, Sweden). A&#946; was defined as CSF A&#946;42 &lt; 192 ng/l.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>13918</offset>
      <text>  </text>
    </passage>
    <passage>
      <infon key="type">table_caption</infon>
      <offset>13921</offset>
      <text>Associations between biomarkers, clinical diagnosis and amyloid pathology</text>
    </passage>
    <passage>
      <infon key="type">table</infon>
      <offset>13995</offset>
      <text>   Comparison CSF T&#8208;tau CSF Ng CSF NFL Difference T&#8208;tau versus Ng Difference T&#8208;tau versus NFL Difference Ng versus NFL   Associations between neurodegeneration biomarkers and A&#946; pathology within diagnostic group  CN A&#946;&#8722; versus CN A&#946;+   0.528 (0.0069)  0.332 (0.087) 0.102 (0.60) 0.197 (0.32)  0.426 (0.031)  0.229 (0.24)  MCI A&#946;&#8722; versus MCI A&#946;+   0.824 (&lt;&#160;0.001)   0.727 (&lt;&#160;0.001)  0.00778 (0.96) 0.0970 (0.61)  0.816 (&lt;&#160;0.001)   0.719 (0.00015)   AD A&#946;&#8722; versus AD A&#946;+   0.789 (0.040)  0.618 (0.11) &#8722;0.632 (0.098) 0.171 (0.67)  1.420 (0.00057)   1.249 (0.0024)   Associations between neurodegeneration biomarkers and combinations of clinical diagnosis and A&#946; pathology  CN A&#946;&#8722; versus CN A&#946;+   0.528 (0.0069)  0.332 (0.087) 0.102 (0.60) 0.197 (0.32)  0.426 (0.031)  0.229 (0.24)  CN A&#946;&#8722; versus MCI A&#946;+   0.916 (&lt;&#160;0.001)   0.816 (&lt;&#160;0.001)   0.798 (&lt;&#160;0.001)  0.100 (0.52) 0.119 (0.45) 0.0185 (0.91)  CN A&#946;&#8722; versus AD A&#946;+   1.172 (&lt;&#160;0.001)   0.860 (&lt;&#160;0.001)   0.973 (&lt;&#160;0.001)   0.312 (0.045)  0.199 (0.20) &#8722;0.113 (0.47)  CN A&#946;&#8722; versus MCI A&#946;&#8722;  0.119 (0.51) 0.120 (0.51)  0.633 (0.00067)  &#8722;0.00141 (0.99)  &#8722;0.514 (0.014)   &#8722;0.513 (0.015)   CN A&#946;&#8722; versus AD A&#946;&#8722;  0.494 (0.18) 0.0564 (0.88)  1.40 (0.00028)  0.438 (0.24)  &#8722;0.909 (0.016)   &#8722;1.35 (0.00040) </text>
    </passage>
    <passage>
      <infon key="type">table_footnote</infon>
      <offset>15311</offset>
      <text>Results for comparisons between different combinations of clinical diagnosis and A&#946; pathology (CN A&#946;&#8722;, n&#160;=&#160;69; CN A&#946;+, n&#160;=&#160;40; MCI A&#946;&#8722;, n&#160;=&#160;50; MCI A&#946;+, n&#160;=&#160;137; AD A&#946;&#8722;, n&#160;=&#160;8; AD A&#946;+, n&#160;=&#160;85) from linear mixed&#8208;effects models testing effects of A&#946; within diagnostic groups (top 3 rows), and differences between A&#946;&#8722; CN and other combinations of A&#946; and diagnosis (bottom 5 rows). The data correspond to Fig&#160;2. Results are &#946;&#8208;coefficient (P&#8208;value). For example, in the top row (&#8220;CN A&#946;&#8722; versus CN A&#946;+&#8221;), the effect of T&#8208;tau indicates that CN A&#946;+ was significantly associated with 0.528 standard deviations higher levels of T&#8208;tau. The columns marked &#8220;difference&#8221; test whether the comparison differed between two biomarkers. For example, in the top row (&#8220;CN A&#946;&#8722; versus CN A&#946;+&#8221;), the difference for T&#8208;tau versus NFL indicates that CN A&#946;+ was significantly more associated with T&#8208;tau than with NFL. Bold values indicate significant associations. CN, healthy controls; MCI, mild cognitive impairment; AD, Alzheimer's disease dementia.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>16404</offset>
      <text>We next compared CSF biomarkers between CN A&#946;&#8722; and all other combinations of diagnosis and A&#946; pathology. These comparisons were based on the theory that AD progresses from CN A&#946;&#8722; to CN A&#946;+, MCI A&#946;+, and finally AD A&#946;+, while non&#8208;A&#946;&#8208;dependent cognitive decline may progress from CN A&#946;&#8722; to MCI A&#946;&#8722; and AD A&#946;&#8722; (we consider these AD A&#946;&#8722; cases to be clinically misdiagnosed). Compared to CN A&#946;&#8722;, T&#8208;tau was increased in CN A&#946;+, MCI A&#946;+, and AD A&#946;+, while Ng was increased in MCI A&#946;+ and AD A&#946;+. In contrast, NFL was increased in all groups with cognitive decline (MCI A&#946;+, AD A&#946;+, MCI A&#946;&#8722;, and AD A&#946;&#8722;).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>17064</offset>
      <text>Finally, we compared the strengths of the associations between CSF biomarkers with different combinations of diagnosis and A&#946; pathology. When comparing them head&#8208;to&#8208;head, T&#8208;tau and Ng had similar strengths of associations with all groups (shown in Table&#160;5 as non&#8208;significant differences for T&#8208;tau and Ng). The only exception was that T&#8208;tau was more strongly associated with AD A&#946;+ (i.e., the difference between CN A&#946;&#8722; and AD A&#946;+ was larger for T&#8208;tau than for Ng; &#946;&#160;=&#160;0.312, P&#160;=&#160;0.045). NFL differed markedly from T&#8208;tau and Ng and was more strongly associated with MCI A&#946;&#8722; and AD A&#946;&#8722; than T&#8208;tau and Ng were (Fig&#160;2 and Table&#160;5).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>17729</offset>
      <text>Associations with cognition, MRI, and FDG&#8208;PET measures</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>17786</offset>
      <text>Finally, we tested associations between biomarkers and cognition, brain structure, brain metabolism, and WMH. Baseline data are shown in Fig&#160;3, and longitudinal data are shown in Fig&#160;4. The models were adjusted for age, sex, and education (for cognitive measures) and intracranial volume (for MRI measures).</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>18096</offset>
      <text>Baseline associations between CSF T&#8208;tau, Ng, and NFL and other AD traits</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>18171</offset>
      <text>Data are estimates (&#946;&#8208;coefficients) from linear mixed&#8208;effects models, with 95% confidence intervals. The estimates are the main effects of the biomarkers, capturing the effects at study baseline. Effects were significant (*) for MMSE (A): T&#8208;tau (P&#160;=&#160;0.034) and NFL (P&#160;&lt;&#160;0.0001) in A&#946;&#8722; for ADAS&#8208;cog (B): NFL in A&#946;&#8722; (P&#160;=&#160;0.0013) and A&#946;+ (P&#160;=&#160;0.024); for hippocampal volume (C): NFL in A&#946;&#8722; (P&#160;&lt;&#160;0.0001); for lateral ventricles (D): T&#8208;tau (P&#160;=&#160;0.0019), Ng (P&#160;=&#160;0.00092), and NFL (P&#160;=&#160;0.0024) in A&#946;&#8722; and T&#8208;tau (P&#160;=&#160;0.00083) and Ng (P&#160;&lt;&#160;0.0001) in A&#946;+ and for FDG&#8208;PET (E): NFL in A&#946;&#8722; (P&#160;=&#160;0.046) and A&#946;+ (P&#160;=&#160;0.0041) people. Biomarkers and outcomes were standardized to z&#8208;scores. Note that the y&#8208;axes for ADAS&#8208;cog, ventricle size, and WMH are flipped, so that the lower ranges constantly reflect &#8220;worse&#8221; outcomes. Note also that the range of the y&#8208;axes differs for the different outcomes, for visualization purposes. Models were adjusted for age and sex, and education (for cognitive measures), and intracranial volume (for MRI measures). A&#946;42 and T&#8208;tau were measured using the INNOBIA AlzBio3 kit (Fujirebio, Ghent, Belgium), Ng was measured using an in&#8208;house immunoassay for Ng (Portelius et&#160;al, 2015), and NFL was measured using the NF&#8208;light&#174; ELISA kit (Uman Diagnostics, Ume&#229;, Sweden).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>19534</offset>
      <text>  </text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>19537</offset>
      <text>Longitudinal associations between CSF T&#8208;tau, Ng, and NFL and other AD traits</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>19616</offset>
      <text>Data are estimates (&#946;&#8208;coefficients) from linear mixed&#8208;effects models, with 95% confidence intervals. The estimates are the effect of time plus the biomarker by time interactions, capturing the longitudinal effects of the biomarkers. For each model, the &#8220;average&#8221; effect of time is also shown for comparison. Effects were significant (*), meaning that biomarker levels affected the slopes of the outcome, for MMSE (A): T&#8208;tau (P&#160;=&#160;0.021) and NFL (P&#160;&lt;&#160;0.0001) in A&#946;&#8722; and for T&#8208;tau (P&#160;&lt;&#160;0.0001), Ng (P&#160;=&#160;0.0031) and NFL (P&#160;&lt;&#160;0.0001) in A&#946;+ for ADAS&#8208;cog (B): NFL in A&#946;&#8722; (P&#160;&lt;&#160;0.0001) and for T&#8208;tau (P&#160;&lt;&#160;0.0001), Ng (P&#160;=&#160;0.0015) and NFL (P&#160;=&#160;0.0027) in A&#946;+ for hippocampal volume (C): NFL in A&#946;&#8722; (P&#160;=&#160;0.0048) and for T&#8208;tau (P&#160;=&#160;0.0015) and Ng (P&#160;=&#160;0.0027) in A&#946;+ for lateral ventricles (D): Ng (P&#160;=&#160;0.0051) and NFL (P&#160;&lt;&#160;0.0001) in A&#946;&#8722; and NFL (P&#160;&lt;&#160;0.0001) in A&#946;+; and for FDG&#8208;PET (E): T&#8208;tau (P&#160;=&#160;0.00038) and Ng (P&#160;=&#160;0.0019) in A&#946;+ people. Biomarkers and outcomes were standardized to z&#8208;scores. Note that the y&#8208;axes for ADAS&#8208;cog, ventricle size, and WMH are flipped, so that the lower ranges constantly reflect &#8220;worse&#8221; outcomes. Note also that the range of the y&#8208;axes differs for the different outcomes, for visualization purposes. Models were adjusted for age and sex, and education (for cognitive measures), and intracranial volume (for MRI measures). A&#946;42 and T&#8208;tau were measured using the INNOBIA AlzBio3 kit (Fujirebio, Ghent, Belgium), Ng was measured using an in&#8208;house immunoassay for Ng (Portelius et&#160;al, 2015), and NFL was measured using the NF&#8208;light&#174; ELISA kit (Uman Diagnostics, Ume&#229;, Sweden).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>21310</offset>
      <text>  </text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>21313</offset>
      <text>At baseline, high T&#8208;tau was associated with poor cognition in A&#946;&#8722;. A detailed analysis suggested that this association was driven by the AD A&#946;&#8722; individuals (i.e. subjects with a clinical diagnosis of AD but without evidence of A&#946; pathology, not shown). T&#8208;tau was surprisingly associated with smaller ventricular volumes in both A&#946;&#8722; and A&#946;+. Over time, high T&#8208;tau was associated with worsening cognition (MMSE in A&#946;&#8722; and A&#946;+, ADAS&#8208;cog in A&#946;+), hippocampal atrophy, and hypometabolism (in A&#946;+). Ng was associated with&#160;smaller baseline ventricles in both A&#946;&#8722; and A&#946;+, with worsening cognition, hippocampal atrophy, and hypometabolism over time in A&#946;+, and with slightly slower expansion of ventricle volume in A&#946;&#8722;.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>22064</offset>
      <text>To explore the unexpected associations between high T&#8208;tau and Ng and small baseline ventricles, we performed post hoc analyses within diagnostic subgroups (using ordinary linear regression, adjusted for intracranial volume, age, and sex). We found significant associations between high T&#8208;tau and small baseline ventricles in CN A&#946;&#8722; (&#946;&#160;=&#160;&#8722;0.25, P&#160;=&#160;0.016) and MCI A&#946;+ (&#946;&#160;=&#160;&#8722;0.18, P&#160;=&#160;0.0064) and between high Ng and small baseline ventricles in MCI A&#946;&#8722; (&#946;&#160;=&#160;&#8722;0.39, P&#160;=&#160;0.0020) and MCI A&#946;+ (&#946;&#160;=&#160;&#8722;0.26, P&#160;=&#160;0.0012). Even in groups where the associations were not significant, the highest T&#8208;tau and Ng levels were constantly seen in subjects with small baseline ventricles, and subjects with large baseline ventricles had low T&#8208;tau and Ng (Figs&#160;EV1 and EV2).</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>22864</offset>
      <text>CSF T&#8208;tau and ventricular volume</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>22899</offset>
      <text>Scatter plots showing CSF T&#8208;tau (ng/l) and ventricular volumes (ml) in different diagnostic group, separately for A&#946;&#8208;negative (upper row) and A&#946;&#8208;positive subjects (lower row). The plots illustrate the general observation that very high CSF T&#8208;tau levels are often seen in subjects with relatively small ventricles, independent of diagnostic group and A&#946; status.</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>23271</offset>
      <text>CSF Ng and ventricular volume</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>23301</offset>
      <text>Scatter plots showing CSF Ng (ng/l) and ventricular volumes (ml) in different diagnostic group, separately for A&#946;&#8208;negative (upper row) and A&#946;&#8208;positive subjects (lower row). The plots illustrate the general observation that very high CSF Ng levels are often seen in subjects with relatively small ventricles, independent of diagnostic group and A&#946; status.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>23665</offset>
      <text>NFL had markedly different patterns of association compared to T&#8208;tau and Ng. At baseline, high NFL was associated with worse cognition, smaller hippocampal volumes, larger ventricles and lower FDG&#8208;PET in both A&#946;&#8722; and A&#946;+ people (the effects&#160;were strongest in A&#946;&#8722;). Over time, NFL was associated with worsening cognition (A&#946;&#8722; and A&#946;+), acceleration of hippocampal&#160;atrophy (A&#946;&#8722;), and expansion of ventricles (A&#946;&#8722; and A&#946;+).</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>24110</offset>
      <text>Discussion</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>24121</offset>
      <text>We compared CSF T&#8208;tau, NFL, and Ng, which are all putative biomarkers for neurodegeneration in AD. The main findings were that (i) combining biomarkers improved the diagnostic accuracy for AD versus CN compared to using individual biomarkers; (ii) T&#8208;tau and Ng were highly correlated and associated with A&#946; pathology across clinical stages of AD, while NFL correlated with cognitive decline independent of A&#946; pathology; and (iii) T&#8208;tau and Ng were associated with acceleration of cognitive decline, atrophy, and hypometabolism primarily in the presence of A&#946; pathology, while NFL was associated with decline independent of A&#946; pathology. In sum, our results support that CSF T&#8208;tau and Ng reflect neurodegeneration in AD, while NFL reflects neurodegeneration independent of AD. Combinations of these biomarkers provide partly complimentary information about diagnosis and pathology in people with cognitive decline.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>25047</offset>
      <text>The first main finding was that all biomarkers identified AD versus controls, and combinations improved the diagnostic accuracy compared to using individual biomarkers. The triple combination of T&#8208;tau, Ng, and NFL had the highest AUC, but the increase was small compared to the combination of T&#8208;tau and NFL. However, although combinations of biomarkers significantly increased the accuracy measured by AUC, the biomarker combinations tested here only had modest effects on the proportion of correctly classified people, especially when also adjusting the models for demographics and CSF A&#946;42. For PMCI versus SMCI, T&#8208;tau and Ng, but not NFL, were significant predictors and no combination was significantly better than T&#8208;tau alone. We expected the biomarkers to be less accurate in MCI than in AD dementia, since some SMCI subjects may have non&#8208;AD diseases (e.g., vascular disease or non&#8208;AD tauopathies) reducing the specificity of the biomarkers.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>26008</offset>
      <text>The fact that NFL had high accuracy for AD is in line with several studies showing increased CSF levels of neurofilaments in AD (Rosengren et&#160;al, 1999; Sj&#246;gren et&#160;al, 2001; Hu et&#160;al, 2002; Zetterberg et&#160;al, 2016). However, NFL is also increased in other neurological conditions, including inflammatory diseases (Mattsson et&#160;al, 2010; Christensen et&#160;al, 2013), Creutzfeldt&#8208;Jakob disease (van Eijk et&#160;al, 2010), acute neuronal ischemia (Merisson et&#160;al, 2016), subcortical vascular dementia (Skillb&#228;ck et&#160;al, 2014), atypical parkinsonian disorders (Hall et&#160;al, 2012), and frontotemporal lobe dementia (FTD) (Petzold et&#160;al, 2007; Pijnenburg et&#160;al, 2007; Landqvist Waldo et&#160;al, 2013) where levels correlate with disease severity (Scherling et&#160;al, 2014). More work is needed to scrutinize CSF NFL in biomarker algorithms for differential diagnostics (de Jong et&#160;al, 2007).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>26894</offset>
      <text>The next main finding was that T&#8208;tau and Ng were strongly associated with A&#946; pathology and more advanced clinical stages of AD. Specifically, T&#8208;tau and Ng were associated with A&#946; pathology within diagnostic groups and with increased levels in CN A&#946;+, MCI A&#946;+, and AD A&#946;+ compared to CN A&#946;&#8722;. This links T&#8208;tau and&#160;Ng to A&#946;&#8208;pathology and shows that this association is present&#160;at all clinical stages of AD, including the prodromal and preclinical stages (Dubois et&#160;al, 2016), which is in line with other recent reports on Ng in other cohorts (Hellwig et&#160;al, 2015; Tarawneh et&#160;al, 2016). In contrast, NFL was not associated with A&#946;&#8208;pathology within diagnostic groups and was increased also in MCI A&#946;&#8722; and AD A&#946;&#8722; participants compared to CN A&#946;&#8722;. This shows that CSF NFL is a non&#8208;specific marker of injury, which is not primarily related to AD. This is consistent with previous reports on increased CSF NFL in different neurological conditions, as explained above.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>27889</offset>
      <text>The next finding was that the biomarkers had different relationships with different outcomes. T&#8208;tau and Ng primarily had associations with deterioration in the presence of A&#946; pathology, which was seen in longitudinal analyses of cognition, hippocampal atrophy, and hypometabolism. In contrast, NFL had associations with cognition, ventricular expansion, and hypometabolism in both A&#946;&#8722; and A&#946;+ people and with longitudinal hippocampal atrophy only in A&#946;&#8722; people. Taken together, these results are compatible with a model where non&#8208;A&#946; and non&#8208;tau pathologies (which may include vascular pathology, TDP&#8208;43, Lewy bodies and other pathologies) are associated with high NFL levels, expansion of ventricles, and some degree of hippocampal atrophy at baseline, but the progressive hippocampal volume loss seen in people harboring A&#946; pathology is independent of NFL and is instead reflected by increased CSF levels of T&#8208;tau and Ng.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>28832</offset>
      <text>Unexpectedly, we found negative associations between T&#8208;tau and Ng and ventricle size at baseline. One possible interpretation of this is that T&#8208;tau and Ng not only reflect neuronal injury, but may also be related to normal neuronal function or transmission, hypothetically resulting in a relationship between high biomarker levels and small ventricle volume. Another unexpected finding was that when we combined T&#8208;tau and Ng in one model for AD diagnosis, the sign for Ng (but not T&#8208;tau) was reversed compared to when it was used alone (Table&#160;3). This indicates that when Ng is used alone to predict AD, high levels are associated with disease, but when it is adjusted for T&#8208;tau, low levels are associated with disease. This finding fits with our speculation that Ng partly reflects normal neuronal function. More in&#8208;depth studies are needed to clarify mechanisms affecting CSF Ng levels in contrast to CSF T&#8208;tau. One recent study found that Ng increases over time in cognitively normal people (Kester et&#160;al, 2015). The reason for this is unknown, but further longitudinal studies will be important to clarify the role of these biomarkers.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>29988</offset>
      <text>Several recent studies on Ng in AD have been published by us and other groups (Portelius et&#160;al, 2015; Tarawneh et&#160;al, 2016; Wellington et&#160;al, 2016). Compared to these, our study is novel by simultaneously investigating CSF T&#8208;tau, Ng, and NFL and by testing whether these biomarkers provide independent information about AD diagnosis and brain changes associated with AD in several different clinical stages of the disease. However, our study is not without limitations. We did not include non&#8208;AD neurodegenerative diseases, and we did not include neuropathology data. For the comparison between PMCI and SMCI, we only included SMCI subjects who were stable for at least 2&#160;years to reduce the number of subjects erroneously classified as stable. However, it is possible that some SMCI subjects would have progressed to AD dementia with longer follow&#8208;up. A final limitation is that we used a fixed cut&#8208;point of CSF A&#946;42 (192&#160;ng/l) to test the effects of brain A&#946; pathology, although it is possible that there may be subtle effects of emerging A&#946; pathology in subjects with slightly higher CSF A&#946;42 levels (Mattsson et&#160;al, 2014, 2015b; Insel et&#160;al, 2015, 2016).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>31166</offset>
      <text>T&#8208;tau, NFL, and Ng contribute independent information in characterization of CN, MCI, and AD. Combinations of these biomarkers, particularly T&#8208;tau and NFL, may increase the diagnostic accuracy of AD. T&#8208;tau and Ng are closely associated with A&#946; pathology at all clinical stages of AD. The independent roles of Ng and T&#8208;tau need further clarification. In contrast to T&#8208;tau and Ng, NFL reflects neurodegeneration that is not associated with A&#946; pathology. Future studies may explore whether CSF T&#8208;tau, Ng, and NFL respond differently to successful disease&#8208;modifying treatment against AD.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>31766</offset>
      <text>Materials and Methods</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>31788</offset>
      <text>ADNI study design</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>31806</offset>
      <text>Data were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The principal investigator of this initiative is Michael W. Weiner, MD, VA Medical Center and University of California, San Francisco. ADNI subjects have been recruited from over 50 sites across the USA and Canada (for up&#8208;to&#8208;date information, see http://www.adni-info.org). Regional ethical committees of all institutions approved of the study. All subjects provided informed consent.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>32304</offset>
      <text>ADNI subjects</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>32318</offset>
      <text>We included all CN, MCI, and AD dementia subjects with available T&#8208;tau, NFL, and Ng data. Inclusion/exclusion criteria are described at http://www.adni-info.org. Briefly, all subjects included were between the ages of 55 and 90&#160;years, had completed at least 6&#160;years of education, were fluent in Spanish or English, and were free of any significant neurological disease other than AD. CN had Mini Mental State Examination (MMSE) score &#8805;&#160;24 and Clinical Dementia Rating (CDR) score 0. MCI had MMSE score &#8805;&#160;24, objective memory loss as shown on scores on delayed recall of the Wechsler Memory Scale Logical Memory II (&gt;&#160;1 standard deviations below the normal mean), CDR 0.5, preserved activities of daily living, and absence of dementia. AD dementia patients fulfilled the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS&#8208;ADRDA) criteria for probable AD (McKhann et&#160;al, 1984) and had MMSE 20&#8211;26 and CDR 0.5&#8211;1.0. For some analyses, we contrasted PMCI versus SMCI. We defined PMCI as MCI subjects converting to AD dementia anytime during follow&#8208;up and SMCI as MCI subjects not converting to AD dementia during at least 2&#160;year of follow&#8208;up.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>33571</offset>
      <text>CSF measurements</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>33588</offset>
      <text>CSF procedures have been described previously (Shaw et&#160;al, 2009). A&#946;42, T&#8208;tau, and P&#8208;tau were measured at the ADNI biomarker core (University of Pennsylvania) using the multiplex xMAP Luminex platform (Luminex Corp, Austin, TX, USA) with the INNOBIA AlzBio3 kit (Fujirebio, Ghent, Belgium). Ng and NFL were measured at the Clinical Neurochemistry Laboratory at University of Gothenburg, M&#246;lndal, Sweden, using an in&#8208;house immunoassay for Ng (Portelius et&#160;al, 2015) and a commercial ELISA for NFL (NF&#8208;light&#174; ELISA, Uman Diagnostics, Ume&#229;, Sweden) (Zetterberg et&#160;al, 2016). We excluded two subjects who were significant outliers in Ng measurements (CSF Ng &gt;&#160;2,000&#160;ng/l).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>34274</offset>
      <text>Cognition</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>34284</offset>
      <text>Cognition was assessed by MMSE and ADAS&#8208;Cog11 up to 13 times: baseline and at 6, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, and 120&#160;months after baseline.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>34440</offset>
      <text>Brain structure</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>34456</offset>
      <text>Structural magnetic resonance imaging brain scans were acquired using 1.5 Tesla MRI scanners up to nine times: baseline and at 6, 12, 18, 24, 36, 48, 60, and 72&#160;months. We used a standardized protocol including T1&#8208;weighted MRI scans using a sagittal volumetric magnetization prepared rapid gradient echo (MP&#8208;RAGE) sequence (Jack et&#160;al, 2008). Automated volume measures were performed with FreeSurfer. We used averaged volume measurements for the right and left hippocampi and combined volumes for the lateral ventricles.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>34983</offset>
      <text>Brain metabolism</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>35000</offset>
      <text>FDG&#8208;PET image data were acquired up to 11 times (baseline and at 6, 12, 18, 24, 36, 48, 60, 72, 84, and 96&#160;months after baseline) (Landau et&#160;al, 2012). We used mean FDG&#8208;PET counts of the lateral and medial frontal, anterior, and posterior cingulate, lateral parietal, and lateral temporal regions.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>35304</offset>
      <text>White matter hyperintensities</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>35334</offset>
      <text>White matter hyperintensities (WMH) were quantified up to seven times (baseline and at 6, 12, 18, 24, 36, and 48&#160;months after baseline) using a fully automated protocol (Schwarz et&#160;al, 2009).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>35528</offset>
      <text>Statistical analysis</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>35549</offset>
      <text>Nonparametric tests (Kruskal&#8211;Wallis, Mann&#8211;Whitney U, and Spearman correlation) were used to test associations between biomarkers and demographic factors. The main analyses consisted of 4 different parts:</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>35757</offset>
      <text>Diagnostic accuracies were tested in logistic regression models separately for AD versus CN and PMCI versus SMCI. All models were evaluated for significance of the included biomarkers, overall diagnostic accuracy (area under the receiver operator characteristics curve, AUC), and overall fit penalized for the number of predictors (Akaike information criterion, AIC). Differences between AUCs were calculated in a bootstrap procedure with resampling (B&#160;=&#160;1,000 iterations). We also tested models adjusted for age, sex, education, and CSF A&#946;42. We extracted classification tables from the logistic regression models to quantify correct classifications of AD, CN, PMCI, and SMCI, using a 50% threshold of predicted probability.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>36486</offset>
      <text>We next tested the effects of A&#946; on biomarkers within diagnostic groups. We dichotomized each diagnostic group using a previously established cutoff of CSF A&#946;42 (&lt;&#160;192&#160;ng/l; Shaw et&#160;al, 2009) and compared A&#946;&#8722; versus A&#946;+. CSF biomarkers were standardized and concatenated into a single response vector, which was used as the dependent variable in linear mixed&#8208;effects models. The independent variable was an interaction between A&#946; and a factor for biomarker type, adjusted for both main effects, age, and sex. All models included a random intercept. The interaction between A&#946; and biomarker type is an estimate of the different effect of A&#946; in two different CSF biomarkers.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>37180</offset>
      <text>We next tested the combination of diagnostic group and A&#946; status as predictor (&#8220;group&#8221;). We hypothesized that AD progresses from CN A&#946;&#8722; to CN A&#946;+, MCI A&#946;+, and AD A&#946;+. In this paradigm, MCI A&#946;&#8722; and AD A&#946;&#8722; represent non&#8208;AD causes of cognitive decline (we consider the AD A&#946;&#8722; cases likely to be clinically misdiagnosed). We again used linear mixed&#8208;effects model with concatenated CSF biomarker levels as the response, and an interaction between &#8220;group&#8221; and a factor for biomarker type as predictor (with CN A&#946;&#8722; as the reference group), adjusted for age and sex.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>37771</offset>
      <text>Finally, we tested CSF biomarkers as predictors of different AD features, including MMSE, ADAS&#8208;cog, hippocampal volume, ventricular volume, FDG&#8208;PET, and WMH. This was done with longitudinal response data, using linear mixed&#8208;effects models. The predictors were a biomarker by time (years) interaction, age, sex, diagnosis (CN, MCI, and AD), and all main effects. Cognition was also adjusted for education and volume measures for intracranial volume. The models included random intercepts and slopes and an unstructured covariance matrix for the random effects. Models were tested separately for A&#946;&#8722; and A&#946;+ people.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>38395</offset>
      <text>  </text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>38398</offset>
      <text>NFL was used after logarithmic transformation. All continuous variables were standardized (scaled and centered). &#946;&#8208;coefficients from regressions refer to standardized effects (&#946;&#160;=&#160;1 indicates that a 1 standard deviation increase in the tested biomarker was associated with a 1 standard deviation increase in the dependent variable). We checked model assumptions by inspecting residuals (correlations with fitted values and predictors of interest, histograms and q&#8211;q plots). All tests were two sided. Significance was determined at P&#160;&lt;&#160;0.05. All statistics were done using R (v. 3.2.3, The R Foundation for Statistical Computing).</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>39038</offset>
      <text>Author contributions</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>39059</offset>
      <text>NM, KB, and OH involved in study conception and design. MW, EP, HZ, and KB participated in acquisition of data. NM, PI, and OH involved in analysis and interpretation of the data. NM drafted the manuscript. PI, SP, EP, HZ, MW, KB, and OH involved in critical revision of the manuscript.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>39346</offset>
      <text>Conflict of interest</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>39367</offset>
      <text>NM, SP, EP, and OH declare that they have no conflict of interest. HZ and KB are co&#8208;founders of Brain Biomarker Solutions in Gothenburg AB, a GU Venture&#8208;based platform company at the University of Gothenburg. MW has served on the Scientific Advisory Boards for Pfizer, Alzheon, Inc., Eli Lilly; has provided consulting to Synarc, Pfizer, Janssen, Alzheimer's Drug Discovery Foundation (ADDF), Avid Radiopharmaceuticals, Araclon, Merck, Biogen Idec, BioClinica, and Genentech; holds stock options with Alzheon, Inc; and has received funding for academic travel from Pfizer, Kenes, Intl., UCSD; ADCS, University Center Hospital, Toulouse, Araclon, AC Immune, Nutricia, Eli Lilly, New York Academy of Sciences (NYAS), The Alzheimer's Association, Merck, Alzheimer's Drug Discovery Foundation (ADDF), Tokyo University, Kyoto University, Weill&#8208;Cornell University, Rockafeller University, Memorial Sloan&#8208;Kettering Cancer Center, and Biogen Idec.</text>
    </passage>
    <passage>
      <infon key="type">title_1_caption</infon>
      <offset>40315</offset>
      <text>The paper explained</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>40335</offset>
      <text>Problem</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>40343</offset>
      <text>Several cerebrospinal fluid biomarkers have been suggested to measure neurodegeneration in Alzheimer's disease. It is unclear to what degree these different biomarkers provide similar or complementary information.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>40557</offset>
      <text>Results</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>40565</offset>
      <text>Cerebrospinal fluid total tau, neurogranin, and neurofilament light represent different aspects of neurodegeneration in Alzheimer's disease. Combinations of these biomarkers improve the diagnostic accuracy compared to using individual biomarkers. Total tau and neurogranin are highly correlated and primarily correlate with degeneration in the presence of A&#946; pathology. Neurofilament light correlates with degeneration independent of A&#946; pathology.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>41019</offset>
      <text>Impact</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>41026</offset>
      <text>Total tau and neurogranin may be used to detect A&#946;&#8208;dependent neurodegeneration, while neurofilament light may be used to monitor degeneration independent of A&#946; pathology. This may have consequences for work&#8208;up in clinical practice and for enrichment and follow&#8208;up in clinical trials of Alzheimer's disease.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>41341</offset>
      <text>For more information</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>41362</offset>
      <text>ADNI, http://adni.loni.usc.edu </text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>41394</offset>
      <text>Supporting information</text>
    </passage>
    <passage>
      <infon key="type">title</infon>
      <offset>41417</offset>
      <text>References</text>
    </passage>
    <passage>
      <infon key="volume">7</infon>
      <infon key="source">Alzheimers Dement</infon>
      <infon key="lpage">279</infon>
      <infon key="pub-id_pmid">21514249</infon>
      <infon key="fpage">270</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>41428</offset>
      <text>The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging&#8208;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</text>
    </passage>
    <passage>
      <infon key="volume">368</infon>
      <infon key="source">Lancet</infon>
      <infon key="lpage">403</infon>
      <infon key="pub-id_pmid">16876668</infon>
      <infon key="fpage">387</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>41638</offset>
      <text>Alzheimer's disease</text>
    </passage>
    <passage>
      <infon key="volume">19</infon>
      <infon key="lpage">884</infon>
      <infon key="source">Mult Scler J</infon>
      <infon key="fpage">877</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>41658</offset>
      <text>CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis</text>
    </passage>
    <passage>
      <infon key="volume">13</infon>
      <infon key="source">Neuropsychol Rev</infon>
      <infon key="lpage">92</infon>
      <infon key="pub-id_pmid">12887040</infon>
      <infon key="fpage">79</infon>
      <infon key="year">2003</infon>
      <infon key="type">ref</infon>
      <offset>41755</offset>
      <text>Alzheimer's disease as a disconnection syndrome?</text>
    </passage>
    <passage>
      <infon key="volume">13</infon>
      <infon key="source">Lancet Neurol</infon>
      <infon key="lpage">629</infon>
      <infon key="pub-id_pmid">24849862</infon>
      <infon key="fpage">614</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>41804</offset>
      <text>Advancing research diagnostic criteria for Alzheimer's disease: the IWG&#8208;2 criteria</text>
    </passage>
    <passage>
      <infon key="volume">12</infon>
      <infon key="lpage">323</infon>
      <infon key="source">Alzheimers Dement J Alzheimers Assoc</infon>
      <infon key="fpage">292</infon>
      <infon key="year">2016</infon>
      <infon key="type">ref</infon>
      <offset>41889</offset>
      <text>Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria</text>
    </passage>
    <passage>
      <infon key="volume">21</infon>
      <infon key="source">J Alzheimers Dis</infon>
      <infon key="lpage">576</infon>
      <infon key="pub-id_pmid">20555148</infon>
      <infon key="fpage">569</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>41975</offset>
      <text>CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt&#8208;Jakob disease</text>
    </passage>
    <passage>
      <infon key="volume">15</infon>
      <infon key="source">Mol Neurobiol</infon>
      <infon key="lpage">163</infon>
      <infon key="pub-id_pmid">9396008</infon>
      <infon key="fpage">131</infon>
      <infon key="year">1997</infon>
      <infon key="type">ref</infon>
      <offset>42062</offset>
      <text>RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes</text>
    </passage>
    <passage>
      <infon key="volume">69</infon>
      <infon key="source">Arch Neurol</infon>
      <infon key="lpage">1452</infon>
      <infon key="pub-id_pmid">22925882</infon>
      <infon key="fpage">1445</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>42160</offset>
      <text>Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders</text>
    </passage>
    <passage>
      <infon key="source">Alzheimers Res Ther</infon>
      <infon key="volume">7</infon>
      <infon key="pub-id_pmid">26698298</infon>
      <infon key="fpage">74</infon>
      <infon key="year">2015</infon>
      <infon key="type">ref</infon>
      <offset>42302</offset>
      <text>Neurogranin and YKL&#8208;40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease</text>
    </passage>
    <passage>
      <infon key="volume">320</infon>
      <infon key="source">Neurosci Lett</infon>
      <infon key="lpage">160</infon>
      <infon key="pub-id_pmid">11852185</infon>
      <infon key="fpage">156</infon>
      <infon key="year">2002</infon>
      <infon key="type">ref</infon>
      <offset>42418</offset>
      <text>Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients</text>
    </passage>
    <passage>
      <infon key="volume">11</infon>
      <infon key="lpage">1179</infon>
      <infon key="source">Alzheimers Dement J Alzheimers Assoc</infon>
      <infon key="fpage">1171</infon>
      <infon key="year">2015</infon>
      <infon key="type">ref</infon>
      <offset>42528</offset>
      <text>The transitional association between &#946;&#8208;amyloid pathology and regional brain atrophy</text>
    </passage>
    <passage>
      <infon key="volume">86</infon>
      <infon key="source">Neurology</infon>
      <infon key="lpage">1896</infon>
      <infon key="pub-id_pmid">27164667</infon>
      <infon key="fpage">1887</infon>
      <infon key="year">2016</infon>
      <infon key="type">ref</infon>
      <offset>42615</offset>
      <text>Accelerating rates of cognitive decline and imaging markers associated with &#946;&#8208;amyloid pathology</text>
    </passage>
    <passage>
      <infon key="volume">27</infon>
      <infon key="source">J Magn Reson Imaging</infon>
      <infon key="lpage">691</infon>
      <infon key="pub-id_pmid">18302232</infon>
      <infon key="fpage">685</infon>
      <infon key="year">2008</infon>
      <infon key="type">ref</infon>
      <offset>42714</offset>
      <text>The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods</text>
    </passage>
    <passage>
      <infon key="volume">3</infon>
      <infon key="source">Ann Clin Transl Neurol</infon>
      <infon key="lpage">20</infon>
      <infon key="pub-id_pmid">26783546</infon>
      <infon key="fpage">12</infon>
      <infon key="year">2016</infon>
      <infon key="type">ref</infon>
      <offset>42782</offset>
      <text>Cerebrospinal fluid neurogranin and YKL&#8208;40 as biomarkers of Alzheimer's disease</text>
    </passage>
    <passage>
      <infon key="volume">78</infon>
      <infon key="source">J Neurol Neurosurg Psychiatry</infon>
      <infon key="lpage">938</infon>
      <infon key="pub-id_pmid">17314187</infon>
      <infon key="fpage">936</infon>
      <infon key="year">2007</infon>
      <infon key="type">ref</infon>
      <offset>42864</offset>
      <text>CSF neurofilament proteins in the differential diagnosis of dementia</text>
    </passage>
    <passage>
      <infon key="volume">72</infon>
      <infon key="source">JAMA Neurol</infon>
      <infon key="lpage">1280</infon>
      <infon key="pub-id_pmid">26366630</infon>
      <infon key="fpage">1275</infon>
      <infon key="year">2015</infon>
      <infon key="type">ref</infon>
      <offset>42933</offset>
      <text>Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease</text>
    </passage>
    <passage>
      <infon key="volume">11</infon>
      <infon key="lpage">1190</infon>
      <infon key="source">Alzheimers Dement J Alzheimers Assoc</infon>
      <infon key="fpage">1180</infon>
      <infon key="year">2015</infon>
      <infon key="type">ref</infon>
      <offset>43031</offset>
      <text>Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease</text>
    </passage>
    <passage>
      <infon key="volume">72</infon>
      <infon key="source">Ann Neurol</infon>
      <infon key="lpage">586</infon>
      <infon key="pub-id_pmid">23109153</infon>
      <infon key="fpage">578</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>43161</offset>
      <text>Amyloid deposition, hypometabolism, and longitudinal cognitive decline</text>
    </passage>
    <passage>
      <infon key="source">BMC Neurol</infon>
      <infon key="volume">13</infon>
      <infon key="pub-id_pmid">23718879</infon>
      <infon key="fpage">54</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>43232</offset>
      <text>Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia</text>
    </passage>
    <passage>
      <infon key="volume">302</infon>
      <infon key="source">JAMA</infon>
      <infon key="lpage">393</infon>
      <infon key="pub-id_pmid">19622817</infon>
      <infon key="fpage">385</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>43332</offset>
      <text>CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment</text>
    </passage>
    <passage>
      <infon key="source">BMC Neurol</infon>
      <infon key="volume">10</infon>
      <infon key="pub-id_pmid">20569437</infon>
      <infon key="fpage">51</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>43422</offset>
      <text>Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism</text>
    </passage>
    <passage>
      <infon key="volume">71</infon>
      <infon key="source">JAMA Neurol</infon>
      <infon key="lpage">734</infon>
      <infon key="pub-id_pmid">24781145</infon>
      <infon key="fpage">725</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>43492</offset>
      <text>Emerging &#946;&#8208;amyloid pathology and accelerated cortical atrophy</text>
    </passage>
    <passage>
      <infon key="volume">1</infon>
      <infon key="lpage">419</infon>
      <infon key="source">Alzheimers Dement Diagn Assess Dis Monit</infon>
      <infon key="fpage">412</infon>
      <infon key="year">2015a</infon>
      <infon key="type">ref</infon>
      <offset>43557</offset>
      <text>Revolutionizing Alzheimer's disease and clinical trials through biomarkers</text>
    </passage>
    <passage>
      <infon key="volume">72</infon>
      <infon key="source">JAMA Neurol</infon>
      <infon key="lpage">560</infon>
      <infon key="pub-id_pmid">25775167</infon>
      <infon key="fpage">554</infon>
      <infon key="year">2015b</infon>
      <infon key="type">ref</infon>
      <offset>43632</offset>
      <text>Predicting reduction of cerebrospinal fluid &#946;&#8208;amyloid 42 in cognitively healthy controls</text>
    </passage>
    <passage>
      <infon key="volume">34</infon>
      <infon key="source">Neurology</infon>
      <infon key="lpage">944</infon>
      <infon key="pub-id_pmid">6610841</infon>
      <infon key="fpage">939</infon>
      <infon key="year">1984</infon>
      <infon key="type">ref</infon>
      <offset>43724</offset>
      <text>Clinical diagnosis of Alzheimer's disease: report of the NINCDS&#8208;ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</text>
    </passage>
    <passage>
      <infon key="volume">7</infon>
      <infon key="lpage">269</infon>
      <infon key="source">Alzheimers Dement J Alzheimers Assoc</infon>
      <infon key="fpage">263</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>43903</offset>
      <text>The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging&#8208;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</text>
    </passage>
    <passage>
      <infon key="volume">93</infon>
      <infon key="source">Neurochem Int</infon>
      <infon key="lpage">5</infon>
      <infon key="pub-id_pmid">26682901</infon>
      <infon key="fpage">1</infon>
      <infon key="year">2016</infon>
      <infon key="type">ref</infon>
      <offset>44096</offset>
      <text>Total&#8208;tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair</text>
    </passage>
    <passage>
      <infon key="volume">8</infon>
      <infon key="source">Alzheimers Dement J Alzheimers Assoc</infon>
      <infon key="type">ref</infon>
      <infon key="fpage">S78&#8208;87</infon>
      <infon key="year">2012</infon>
      <offset>44202</offset>
      <text>White matter atrophy in Alzheimer's disease variants</text>
    </passage>
    <passage>
      <infon key="volume">4</infon>
      <infon key="source">Neurodegener Dis</infon>
      <infon key="lpage">194</infon>
      <infon key="pub-id_pmid">17596713</infon>
      <infon key="fpage">185</infon>
      <infon key="year">2007</infon>
      <infon key="type">ref</infon>
      <offset>44255</offset>
      <text>A systematic review and meta&#8208;analysis of CSF neurofilament protein levels as biomarkers in dementia</text>
    </passage>
    <passage>
      <infon key="volume">23</infon>
      <infon key="source">Dement Geriatr Cogn Disord</infon>
      <infon key="lpage">230</infon>
      <infon key="pub-id_pmid">17290105</infon>
      <infon key="fpage">225</infon>
      <infon key="year">2007</infon>
      <infon key="type">ref</infon>
      <offset>44357</offset>
      <text>CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls</text>
    </passage>
    <passage>
      <infon key="volume">138</infon>
      <infon key="lpage">3385</infon>
      <infon key="source">Brain J Neurol</infon>
      <infon key="fpage">3373</infon>
      <infon key="year">2015</infon>
      <infon key="type">ref</infon>
      <offset>44462</offset>
      <text>Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease</text>
    </passage>
    <passage>
      <infon key="volume">52</infon>
      <infon key="source">Neurology</infon>
      <infon key="lpage">1093</infon>
      <infon key="pub-id_pmid">10102440</infon>
      <infon key="fpage">1090</infon>
      <infon key="year">1999</infon>
      <infon key="type">ref</infon>
      <offset>44562</offset>
      <text>Neurofilament protein levels in CSF are increased in dementia</text>
    </passage>
    <passage>
      <infon key="volume">75</infon>
      <infon key="source">Ann Neurol</infon>
      <infon key="lpage">126</infon>
      <infon key="pub-id_pmid">24242746</infon>
      <infon key="fpage">116</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>44624</offset>
      <text>Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration</text>
    </passage>
    <passage>
      <infon key="volume">21</infon>
      <infon key="lpage">251</infon>
      <infon key="source">Inf Process Med Imaging Proc Conf</infon>
      <infon key="fpage">239</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>44729</offset>
      <text>Fully&#8208;automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR</text>
    </passage>
    <passage>
      <infon key="volume">65</infon>
      <infon key="source">Ann Neurol</infon>
      <infon key="lpage">413</infon>
      <infon key="pub-id_pmid">19296504</infon>
      <infon key="fpage">403</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>44835</offset>
      <text>Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects</text>
    </passage>
    <passage>
      <infon key="volume">66</infon>
      <infon key="source">J Neurosci Res</infon>
      <infon key="lpage">516</infon>
      <infon key="pub-id_pmid">11746370</infon>
      <infon key="fpage">510</infon>
      <infon key="year">2001</infon>
      <infon key="type">ref</infon>
      <offset>44931</offset>
      <text>Neurofilament protein in cerebrospinal fluid: a marker of white matter changes</text>
    </passage>
    <passage>
      <infon key="volume">83</infon>
      <infon key="source">Neurology</infon>
      <infon key="lpage">1953</infon>
      <infon key="pub-id_pmid">25339208</infon>
      <infon key="fpage">1945</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>45010</offset>
      <text>CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival</text>
    </passage>
    <passage>
      <infon key="volume">7</infon>
      <infon key="lpage">292</infon>
      <infon key="source">Alzheimers Dement J Alzheimers Assoc</infon>
      <infon key="fpage">280</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>45107</offset>
      <text>Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging&#8208;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</text>
    </passage>
    <passage>
      <infon key="volume">73</infon>
      <infon key="source">JAMA Neurol</infon>
      <infon key="lpage">571</infon>
      <infon key="pub-id_pmid">27018940</infon>
      <infon key="fpage">561</infon>
      <infon key="year">2016</infon>
      <infon key="type">ref</infon>
      <offset>45309</offset>
      <text>Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease</text>
    </passage>
    <passage>
      <infon key="volume">86</infon>
      <infon key="source">Neurology</infon>
      <infon key="lpage">835</infon>
      <infon key="pub-id_pmid">26826204</infon>
      <infon key="fpage">829</infon>
      <infon key="year">2016</infon>
      <infon key="type">ref</infon>
      <offset>45399</offset>
      <text>Increased CSF neurogranin concentration is specific to Alzheimer disease</text>
    </passage>
    <passage>
      <infon key="volume">73</infon>
      <infon key="source">JAMA Neurol</infon>
      <infon key="lpage">67</infon>
      <infon key="pub-id_pmid">26524180</infon>
      <infon key="fpage">60</infon>
      <infon key="year">2016</infon>
      <infon key="type">ref</infon>
      <offset>45472</offset>
      <text>Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression</text>
    </passage>
  </document>
</collection>
